Trials / Conditions / Relapsed Acute Myeloid Leukemia

Relapsed Acute Myeloid Leukemia

17 registered clinical trials studyying Relapsed Acute Myeloid Leukemia — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Imetelstat Combinations in Relapsed AML NCT07320235	Douglas Tremblay	Phase 1
Recruiting	Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML NCT06561152	Stanford University	Phase 1 / Phase 2
Recruiting	Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML NCT06741722	Beijing 302 Hospital	Phase 2
Recruiting	VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS NCT06536959	Beijing 302 Hospital	Phase 2
Recruiting	Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relap NCT06177067	St. Jude Children's Research Hospital	Phase 1
Recruiting	A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia NCT06017258	Memorial Sloan Kettering Cancer Center	Phase 1
Withdrawn	Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or NCT04354025	Washington University School of Medicine	Phase 2
Terminated	A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Rel NCT05028751	Kronos Bio	Phase 1 / Phase 2
Withdrawn	Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS NCT04893915	Washington University School of Medicine	Phase 2
Unknown	Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloi NCT05362942	Beijing 302 Hospital	Phase 2
Recruiting	Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms NCT04797767	University of Washington	Phase 1 / Phase 2
Active Not Recruiting	FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies NCT04891757	Foghorn Therapeutics Inc.	Phase 1
Terminated	Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic NCT04582864	Washington University School of Medicine	Phase 2
Completed	Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML NCT05456048	Nanfang Hospital, Southern Medical University	—
Completed	Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia NCT02996474	National Heart, Lung, and Blood Institute (NHLBI)	Phase 1 / Phase 2
Terminated	Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML NCT02109627	C. Babis Andreadis	Phase 1
Completed	Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01961765	Massachusetts General Hospital	Phase 1